NO20065860L - Stabiliserte flytende interferonformuleringer - Google Patents

Stabiliserte flytende interferonformuleringer

Info

Publication number
NO20065860L
NO20065860L NO20065860A NO20065860A NO20065860L NO 20065860 L NO20065860 L NO 20065860L NO 20065860 A NO20065860 A NO 20065860A NO 20065860 A NO20065860 A NO 20065860A NO 20065860 L NO20065860 L NO 20065860L
Authority
NO
Norway
Prior art keywords
stabilized liquid
interferon formulations
liquid interferon
interferon
formulations
Prior art date
Application number
NO20065860A
Other languages
English (en)
Norwegian (no)
Inventor
Fabrizio Samaritani
Alessandra Del Rio
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20065860L publication Critical patent/NO20065860L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20065860A 2004-06-01 2006-12-19 Stabiliserte flytende interferonformuleringer NO20065860L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04076626 2004-06-01
US61637804P 2004-10-06 2004-10-06
PCT/EP2005/052414 WO2005117949A1 (en) 2004-06-01 2005-05-27 Stabilized interferon liquid formulations

Publications (1)

Publication Number Publication Date
NO20065860L true NO20065860L (no) 2006-12-19

Family

ID=34928261

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065860A NO20065860L (no) 2004-06-01 2006-12-19 Stabiliserte flytende interferonformuleringer

Country Status (15)

Country Link
US (1) US7731948B2 (zh)
EP (1) EP1750751B1 (zh)
JP (1) JP4988562B2 (zh)
CN (1) CN1993139B (zh)
AU (1) AU2005249233B2 (zh)
BR (1) BRPI0510526A (zh)
CA (1) CA2567310A1 (zh)
EA (1) EA010979B1 (zh)
ES (1) ES2418833T3 (zh)
HK (1) HK1102563A1 (zh)
IL (1) IL179620A (zh)
MX (1) MXPA06014078A (zh)
NO (1) NO20065860L (zh)
UA (1) UA92146C2 (zh)
WO (1) WO2005117949A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4658961B2 (ja) 2003-12-11 2011-03-23 アレス トレーディング エス．エー． 安定化されたインターフェロン液体製剤
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
CA2571800A1 (en) * 2005-12-23 2007-06-23 Canadian Blood Services Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
AU2008269086B2 (en) 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009080699A2 (en) * 2007-12-20 2009-07-02 Merck Serono S.A. Peg-interferon-beta formulations
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
MX359947B (es) * 2011-03-15 2018-10-17 Biogen Ma Inc EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE.
RU2527701C1 (ru) * 2013-05-24 2014-09-10 Федеральное государственное бюджетное учреждение "Научный центр реконструктивной и восстановительной хирургии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦРВХ" СО РАМН) Способ приготовления средства, обладающего свойством стимуляции регенерации хрящевой, костной, мышечной тканей и способ стимуляции регенерации хрящевой, костной, мышечной тканей с использованием приготовленного средства
EP3126379B1 (en) * 2014-04-04 2019-05-22 Ares Trading SA Novel ifn beta protein analogs
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN114053397B (zh) * 2022-01-17 2022-12-20 北京三元基因药业股份有限公司 一种稳定的干扰素多剂量注射液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4469228A (en) 1983-05-31 1984-09-04 Schering Corporation Interferon kit
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1244511B (it) 1991-04-15 1994-07-15 Isi Ist Sierovaccinogeno Ital Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione.
KR960009385B1 (en) * 1993-11-24 1996-07-18 Samsung Bp Chemicals Co Ltd Apparatus and method for wastewater treatment by activated sludge process type
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5858001A (en) 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
AU739469B2 (en) 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
PT1224940E (pt) 1997-09-23 2005-01-31 Rentschler Biotech Gmbh Formulacoes liquidas de intrferao beta
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
CN1187094C (zh) 1998-04-28 2005-02-02 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
NZ517184A (en) 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
HUP0203133A3 (en) * 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6586785B2 (en) 2000-06-29 2003-07-01 California Institute Of Technology Aerosol silicon nanoparticles for use in semiconductor device fabrication
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
DE60130580T2 (de) 2000-12-27 2008-06-12 Ares Trading S.A. Lipidmikropartikel mittels kryogenischer mikronisierung
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
EP1471891A4 (en) 2002-02-08 2007-04-11 Alkermes Inc POLYMER-BASED COMPOSITIONS FOR PROLONGED RELEASE
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations

Also Published As

Publication number Publication date
CN1993139B (zh) 2011-02-16
JP2008500996A (ja) 2008-01-17
US20070292391A1 (en) 2007-12-20
AU2005249233A1 (en) 2005-12-15
WO2005117949A1 (en) 2005-12-15
IL179620A0 (en) 2007-05-15
US7731948B2 (en) 2010-06-08
UA92146C2 (ru) 2010-10-11
IL179620A (en) 2013-04-30
AU2005249233B2 (en) 2010-10-07
CN1993139A (zh) 2007-07-04
JP4988562B2 (ja) 2012-08-01
ES2418833T3 (es) 2013-08-16
EA010979B1 (ru) 2008-12-30
EA200602257A1 (ru) 2007-04-27
EP1750751A1 (en) 2007-02-14
EP1750751B1 (en) 2013-04-10
CA2567310A1 (en) 2005-12-15
HK1102563A1 (en) 2007-11-30
BRPI0510526A (pt) 2007-10-30
MXPA06014078A (es) 2007-02-15

Similar Documents

Publication Publication Date Title
NO20065860L (no) Stabiliserte flytende interferonformuleringer
NO20055666L (no) HSA-frie, stabiliserte flytende utforminger av interferon
BRPI0510654A (pt) formulações de interferon em hidrogel
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
UA93349C2 (ru) Способ стабилизации мономерного белка интерферона
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
MY142354A (en) Acidic insulin preparations having improved stability
ATE382057T1 (de) Stabile formulierung von modifiziertem glp-1
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
NO20054555D0 (no) Farmasoytiske preparater som omfatter syrestabilisert insulin
DK1389137T3 (da) Sammensætninger til lungelægemiddellevering af protein
HRP20050024A2 (en) Pegylated t20 polypeptide
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
ZA200501714B (en) Analogues of vitamin d
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
SE0200657D0 (sv) Novel Formulation
AR034749A1 (es) Formulaciones de interferon beta humano
ATE455471T1 (de) Pulverförmige zusammensetzungen von fettlöslichen substanzen
DK1363676T3 (da) Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre
NO20065853L (no) Hydrogelinterferonformuleringer
ITMI20020639A1 (it) Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
CY1114273T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης χωρις ανθρωπινη οροαλβουμινη
ATE424399T1 (de) Pharmazeutische zusammensetzungen von risperidon in wässriger lösung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application